Proactive Investors - Run By Investors For Investors

4D Pharma's first in man study shows 'encouraging' symptom improvement

Subjects treated with Blautix showed a greater response over placebo, with the majority reporting an overall improvement in their symptoms.
Gut microbiome
"This is a true first in the field of live biotherapeutics."

4D Pharma PLC (LON:DDDD) announced that testing of its IBS live biotherapeutics treatment Blautix has shown meaningful data surrounding mechanism of action, as well as safety and tolerability, with “great efficiency”.

The first in man study was the only orally delivered live biotherapeutic to have undergone a clinical trial.  

Twice daily dosing of 24 healthy volunteers and 24 IBS subjects with either Blautix (16/24) or placebo (8/24) over a 14 day period, with a further washout period of 19-23 days. 

In common with other IBS studies, the study noted a strong placebo response.

However, following the dosing period, subjects treated with Blautix showed a greater response over placebo, with the majority reporting an overall improvement in their symptoms. 

A greater proportion of the Blautix treatment group also exhibited a reduction in hydrogen breath levels following dosing. 

Although based on a relatively small sample size, this observation is in line with pre-clinical data and strengthens the evidence of the proposed mechanism of action for Blautix in the treatment of IBS, namely altering the patient’s microbiome – altering the body’s microbial make-up.

The results show that the treatment is able to successfully deliver a single strain live biotherapeutic to the gut.

4D said the findings of this first clinical trial were encouraging and provide a solid basis for progressing Blautix into larger clinical studies and further evaluation as a potential treatment for IBS.

"This is a true first in the field of live biotherapeutics.  4D has been able to produce an orally delivered live biotherapeutic, and generate meaningful data surrounding mechanism of action, and safety and tolerability, with great efficiency,” said chief executive Duncan Peyton.

"This gives us confidence to progress to the next phase towards approval of a safe, effective treatment in IBS."

Shares were down 7% to 725p.

 

View full DDDD profile View Profile

4D Pharma Timeline

Newswire
June 10 2016

Related Articles

A paper rocket is ready to launch on a surgeon's scissors
March 28 2019
The company hopes to improve its share price with ADAPT technology successes.
Cancer cells
February 06 2019
In October 2018, Maxcyte saw the first patient dosed in an initial phase I trial using its lead MCY-M11 therapy, tracking a total of 15 women with relapsed or hard-to-treat forms of cancer
1557403923_iron.jpg
May 09 2019
Here we take a look under the hood of Shield Therapeutics

© Proactive Investors 2019

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use